Improvement of pre-existing accompanying symptoms other than pain · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Health economic measures · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Weight gain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: weight gain compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Quality of life · People of any age and either sex, in any setting, with BRONJ; bisphosphonate exposure past or current; includes people with cancer and…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · lycopene
Lycopene (Cano-Carrillo 2014) contributes to the dietary supplements short-term symptom-relief comparison (12 RCTs, insufficient/contradictory); no separate lycopene symptom-relief estimate reported.
1 study · 50 participants
GRADE not reported
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
Topical urea 10% (Alvarenga da Silva 2014) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory); no separate estimate reported.
1 study · 38 participants
GRADE not reported
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3 (NSAIDs vs placebo), Cancer development: SoF cell 'Not measured'. Effects text: cancer development was among outcomes in Papadimitrakopoulou 2008 (celecoxib) but did not occur in either arm, probably because of…
1 study
GRADE not reported
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: urinary incontinence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: urinary incontinence compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: gastrointestinal complaints compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life or patient satisfaction · Adolescents/teenagers undergoing orthodontic treatment
Experimental chewing adjuncts (bite wafers or chewing gum) led to lower quality of life or patient satisfaction compared with no chewing gum, placebo, or control (no adjunct); GRADE not reported.
1 finding from 1 review
Adverse effects: mild headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin + alpha lipoic acid) changes adverse effects: mild headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects of pain treatment · Adolescents and adults undergoing orthodontic treatment
The review found no eligible studies for this question.
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether topical treatments (lactoperoxidase oral rinse / Biotene) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review